A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo Controlled, Single-Dose and Multiple-Ascending Dose Study of Orally Administered LY5625573 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein
The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them.
Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
-
Singapore, Singapore, 138623
- Not yet recruiting
- Lilly Centre for Clinical Pharmacology
-
Contact:
- Phone Number: 64139811
-
Principal Investigator:
- Jeffer Hann Wei Pang
-
-
-
-
California
-
Los Alamitos, California, United States, 90720
- Not yet recruiting
- Collaborative Neuroscience Network - CNS
-
Principal Investigator:
- Steven Reynolds
-
-
Texas
-
Dallas, Texas, United States, 75247
- Recruiting
- Fortrea Clinical Research Unit
-
Principal Investigator:
- Gene Voskuhl
-
Contact:
- Phone Number: 866-429-3700
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 21 to 65 years of age, inclusive, at the time of signing the informed consent if enrolled in Singapore
- Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
- Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Have a hemoglobin level of at least 12.5 grams per deciliter (g/dL) for participants assigned male at birth (AMAB) and at least 11.4 g/dL for participants assigned female at birth (AFAB)
- Individuals AFAB who are individual not of childbearing potential (INOCBPs) may participate in this trial
Parts A, B, D, and E
- Have a body mass index (BMI) greater than or equal to (≥)18.5 and less than or equal to (≤) 32.0 kilograms per square meter (kg/m²)
- Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of ≥90 milliliter per minute per 1.73 square meters (mL)/minute/1.73 m² at screening
Part C
- Have a BMI ≥18.5 and <40.0 kg/m²
- high-sensitivity C-reactive protein (hsCRP) ≥2 milligrams per liter (mg/L) and ≤15 mg/L at screening and Day -2 (as confirmed by local laboratory).
- Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m² at screening
Part D
- To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan
Part E
- To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
Exclusion Criteria:
- History of active tuberculosis or presence of active or latent tuberculosis
- History or evidence of clinically significant opportunistic infection
- History of serious local infection (for example, cellulitis or abscess) or systemic infection within 90 days prior to screening
- Have any nonserious but active infections
- History of more than one episode of herpes zoster infection or history of disseminated herpes zoster infection
- Have a 12-lead electrocardiogram (ECG) abnormality
- Clinically significant abnormal laboratory test results at screening, or positive serology test results for hepatitis B surface antigen, hepatitis B core total antibody, hepatitis C virus antibody, or human immunodeficiency virus antigen and antibody, or QuantiFERON®-TB test at screening
Parts A, C, D, and E
- History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232) or to any excipient in the formulation of LY5625573
Part B
- History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232), midazolam, or to any excipient in the formulation of LY5625573 or midazolam
Parts B, C, D, and E
- Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 90 days (at screening and/or Day -1 [Day 2 for Part B])
- Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire (at Day -1[Day 2 for Part B]
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LY5625573 Part A - Single Dose Healthy
Single dose of LY5625573 administered orally in healthy participants |
Administered orally as tablet
Other Names:
|
|
Placebo Comparator: Placebo Part A - Single Dose Healthy
Single dose of Placebo administered orally in healthy participants |
Administered orally as tablet |
|
Experimental: LY5625573 + Midazolam Part B - Multiple Dose Healthy
Multiple-ascending dose (MAD) of LY5625573 and midazolam co-administered orally in healthy participants |
Administered orally Administered orally as tablet
Other Names:
|
|
Placebo Comparator: Placebo + Midazolam Part B - Multiple Dose Healthy
Multiple doses of Placebo and midazolam co-administered orally in healthy participants |
Administered orally Administered orally as tablet |
|
Experimental: LY5625573 Part C - Multiple Dose Elevated hsCRP
MAD of LY5625573 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP) |
Administered orally as tablet
Other Names:
|
|
Placebo Comparator: Placebo Part C - Multiple Dose Elevated hsCRP
Multiple doses of Placebo administered orally in participants with elevated hsCRP |
Administered orally as tablet |
|
Experimental: LY5625573 Part D - Healthy Japanese
MAD of LY5625573 administered orally in healthy Japanese participants |
Administered orally as tablet
Other Names:
|
|
Placebo Comparator: Placebo Part D - Healthy Japanese
Multiple doses of Placebo administered orally in healthy Japanese participants |
Administered orally as tablet |
|
Experimental: LY5625573 Part E - Healthy Chinese
MAD of LY5625573 administered orally in healthy Chinese participants |
Administered orally as tablet
Other Names:
|
|
Placebo Comparator: Placebo Part E - Healthy Chinese
Multiple doses of Placebo administered orally in healthy Chinese participants |
Administered orally as tablet |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline up to Follow up (Days 12 and 24)
|
Baseline up to Follow up (Days 12 and 24)
|
|
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline up to Follow up (Days 12 and 24)
|
Baseline up to Follow up (Days 12 and 24)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY5625573
Time Frame: Baseline up to End of Treatment (Day 17)
|
Baseline up to End of Treatment (Day 17)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 27937
- J7V-MC-EOBB (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.